Tandem Diabetes Care, Inc.

NasdaqGM:TNDM Stok Raporu

Piyasa değeri: US$2.0b

Tandem Diabetes Care Yönetim

Yönetim kriter kontrolleri 4/4

Tandem Diabetes Care CEO'su John Sheridan, Apr2013 tarihinde atandı, in görev süresi 11.58 yıldır. in toplam yıllık tazminatı $ 4.65M olup, şirket hissesi ve opsiyonları dahil olmak üzere 15.3% maaş ve 84.7% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.083% ine doğrudan sahiptir ve bu hisseler $ 1.65M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3.2 yıl ve 4.3 yıldır.

Anahtar bilgiler

John Sheridan

İcra Kurulu Başkanı

US$4.7m

Toplam tazminat

CEO maaş yüzdesi15.3%
CEO görev süresi11.6yrs
CEO sahipliği0.08%
Yönetim ortalama görev süresi3.2yrs
Yönetim Kurulu ortalama görev süresi4.3yrs

Son yönetim güncellemeleri

Recent updates

Slammed 27% Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Screens Well Here But There Might Be A Catch

Nov 16
Slammed 27% Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Screens Well Here But There Might Be A Catch

Health Check: How Prudently Does Tandem Diabetes Care (NASDAQ:TNDM) Use Debt?

Sep 28
Health Check: How Prudently Does Tandem Diabetes Care (NASDAQ:TNDM) Use Debt?

Potential Upside For Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Not Without Risk

Aug 31
Potential Upside For Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Not Without Risk

Tandem Diabetes: Mobi's Surprise Sales Fail To Offset Flat Operating Margin

Aug 14

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Aug 04
Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Is It Time To Consider Buying Tandem Diabetes Care, Inc. (NASDAQ:TNDM)?

Jul 12
Is It Time To Consider Buying Tandem Diabetes Care, Inc. (NASDAQ:TNDM)?

Is Tandem Diabetes Care (NASDAQ:TNDM) Weighed On By Its Debt Load?

Jun 18
Is Tandem Diabetes Care (NASDAQ:TNDM) Weighed On By Its Debt Load?

Tandem Diabetes Care: Recent Rally Fully Deserved, Likely More Upside Here

May 29

Tandem Diabetes Care, Inc.'s (NASDAQ:TNDM) 26% Jump Shows Its Popularity With Investors

May 10
Tandem Diabetes Care, Inc.'s (NASDAQ:TNDM) 26% Jump Shows Its Popularity With Investors

A Look At The Fair Value Of Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

May 04
A Look At The Fair Value Of Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

At US$30.10, Is Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Worth Looking At Closely?

Mar 26
At US$30.10, Is Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Worth Looking At Closely?

Even With A 27% Surge, Cautious Investors Are Not Rewarding Tandem Diabetes Care, Inc.'s (NASDAQ:TNDM) Performance Completely

Mar 08
Even With A 27% Surge, Cautious Investors Are Not Rewarding Tandem Diabetes Care, Inc.'s (NASDAQ:TNDM) Performance Completely

Is Tandem Diabetes Care (NASDAQ:TNDM) Using Debt In A Risky Way?

Feb 22
Is Tandem Diabetes Care (NASDAQ:TNDM) Using Debt In A Risky Way?

Estimating The Intrinsic Value Of Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

Jan 14
Estimating The Intrinsic Value Of Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Stock Rockets 63% But Many Are Still Ignoring The Company

Dec 27
Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Stock Rockets 63% But Many Are Still Ignoring The Company

Is It Too Late To Consider Buying Tandem Diabetes Care, Inc. (NASDAQ:TNDM)?

Nov 12
Is It Too Late To Consider Buying Tandem Diabetes Care, Inc. (NASDAQ:TNDM)?

Tandem Diabetes Care, Inc.'s (NASDAQ:TNDM) Intrinsic Value Is Potentially 53% Above Its Share Price

Oct 06
Tandem Diabetes Care, Inc.'s (NASDAQ:TNDM) Intrinsic Value Is Potentially 53% Above Its Share Price

Does Tandem Diabetes Care (NASDAQ:TNDM) Have A Healthy Balance Sheet?

Sep 17
Does Tandem Diabetes Care (NASDAQ:TNDM) Have A Healthy Balance Sheet?

Should You Think About Buying Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Now?

Aug 08
Should You Think About Buying Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Now?

Calculating The Intrinsic Value Of Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

Jul 03
Calculating The Intrinsic Value Of Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

Is Tandem Diabetes Care (NASDAQ:TNDM) Using Debt Sensibly?

Jun 13
Is Tandem Diabetes Care (NASDAQ:TNDM) Using Debt Sensibly?

Cautious Investors Not Rewarding Tandem Diabetes Care, Inc.'s (NASDAQ:TNDM) Performance Completely

May 06
Cautious Investors Not Rewarding Tandem Diabetes Care, Inc.'s (NASDAQ:TNDM) Performance Completely

Is Tandem Diabetes Care (NASDAQ:TNDM) Using Debt In A Risky Way?

Jan 04
Is Tandem Diabetes Care (NASDAQ:TNDM) Using Debt In A Risky Way?

Is Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Potentially Undervalued?

Oct 15
Is Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Potentially Undervalued?

Tandem Diabetes Care: Overpriced, Underdelivering

Sep 22

An Intrinsic Calculation For Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Suggests It's 50% Undervalued

Sep 10
An Intrinsic Calculation For Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Suggests It's 50% Undervalued

Tandem Diabetes stock falls 10% on disappointing Q2 result

Aug 03

Tandem Diabetes Care acquires Capillary Biomedical; terms undisclosed

Jul 21

Tandem Diabetes Care: Strong Financials And Revenue, Overpenalized For Missed Earnings

Jul 08

Tandem Diabetes Care (NASDAQ:TNDM) Is Looking To Continue Growing Its Returns On Capital

Jun 20
Tandem Diabetes Care (NASDAQ:TNDM) Is Looking To Continue Growing Its Returns On Capital

Tandem Diabetes Care, Inc.'s (NASDAQ:TNDM) Intrinsic Value Is Potentially 43% Above Its Share Price

May 30
Tandem Diabetes Care, Inc.'s (NASDAQ:TNDM) Intrinsic Value Is Potentially 43% Above Its Share Price

CEO Tazminat Analizi

John Sheridan'un ücretlendirmesi Tandem Diabetes Care'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Sep 30 2024n/an/a

-US$127m

Jun 30 2024n/an/a

-US$136m

Mar 31 2024n/an/a

-US$141m

Dec 31 2023US$5mUS$711k

-US$223m

Sep 30 2023n/an/a

-US$208m

Jun 30 2023n/an/a

-US$224m

Mar 31 2023n/an/a

-US$204m

Dec 31 2022US$6mUS$711k

-US$95m

Sep 30 2022n/an/a

-US$68m

Jun 30 2022n/an/a

-US$13m

Mar 31 2022n/an/a

US$6m

Dec 31 2021US$6mUS$690k

US$16m

Sep 30 2021n/an/a

US$22m

Jun 30 2021n/an/a

US$7m

Mar 31 2021n/an/a

-US$25m

Dec 31 2020US$4mUS$600k

-US$34m

Sep 30 2020n/an/a

-US$49m

Jun 30 2020n/an/a

-US$42m

Mar 31 2020n/an/a

-US$17m

Dec 31 2019US$11mUS$500k

-US$25m

Sep 30 2019n/an/a

-US$24m

Jun 30 2019n/an/a

-US$55m

Mar 31 2019n/an/a

-US$113m

Dec 31 2018US$2mUS$386k

-US$123m

Sep 30 2018n/an/a

-US$138m

Jun 30 2018n/an/a

-US$119m

Mar 31 2018n/an/a

-US$82m

Dec 31 2017US$596kUS$375k

-US$73m

Tazminat ve Piyasa: John 'ın toplam tazminatı ($USD 4.65M ) US pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 5.57M ).

Tazminat ve Kazançlar: John 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.


CEO

John Sheridan (69 yo)

11.6yrs

Görev süresi

US$4,651,603

Tazminat

Mr. John F. Sheridan has been President and Chief Executive Officer at Tandem Diabetes Care, Inc., since March 01, 2019 and served as its Chief Operating Officer and Executive Vice President since April 20...


Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
John Sheridan
President11.6yrsUS$4.65m0.083%
$ 1.7m
Leigh Vosseller
Executive VP6.8yrsUS$1.25m0.051%
$ 1.0m
Susan Morrison
Executive VP & Chief Administrative Officer11.2yrsUS$1.25m0.038%
$ 757.4k
David Berger
Transitional Advisorless than a yearUS$1.25m0.011%
$ 212.4k
Elizabeth Gasser
Executive Vice President and Chief Strategy & Product Officer3.4yrsUS$1.25m0.022%
$ 448.3k
Mark Novara
Executive VP & Chief Commercial Officerless than a yearUS$2.72m0.00081%
$ 16.2k
Jean-Claude Kyrillos
Executive VP & COOless than a yearVeri yokVeri yok
Rick Carpenter
Chief Technical Officer3yrsVeri yok0.022%
$ 446.3k
Shannon Hansen
Executive VP2.8yrsVeri yok0.020%
$ 408.8k
Tom Fox
Chief Human Resources Officer7.3yrsVeri yokVeri yok
Jordan Pinsker
Chief Medical Officerless than a yearVeri yokVeri yok
James Leal
Chief Manufacturing Officer7.3yrsVeri yok0.026%
$ 513.5k

3.2yrs

Ortalama Görev Süresi

56yo

Ortalama Yaş

Deneyimli Yönetim: TNDM 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.2 yıldır).


Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
John Sheridan
President5.4yrsUS$4.65m0.083%
$ 1.7m
Rebecca Robertson
Independent Chairwoman of the Board5.8yrsUS$222.78k0.014%
$ 285.9k
Kim Blickenstaff
Chair Emeritusless than a yearUS$198.78k0.28%
$ 5.6m
Christopher Twomey
Independent Director11.3yrsUS$200.95k0.036%
$ 729.0k
Dick Allen
Independent Director17.3yrsUS$214.67k0.059%
$ 1.2m
Peyton Howell
Independent Director4.3yrsUS$190.28k0.025%
$ 507.7k
Rajwant Sodhi
Independent Director3.8yrsUS$189.25k0.017%
$ 338.6k
Kathleen McGroddy-Goetz
Independent Director4.4yrsUS$189.25k0.021%
$ 409.6k
Myoungil Cha
Independent Director2.4yrsUS$176.55k0.012%
$ 230.2k
Joao Paulo Malagueira
Independent Director2.4yrsUS$177.55k0.012%
$ 230.2k

4.3yrs

Ortalama Görev Süresi

61.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: TNDM 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4.3 yıldır).